搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按时间排序
按相关度排序
4 天
RBC维持Ideaya Biosciences目标价,看好daro前景
RBC Capital维持Ideaya Biosciences (NASDAQ:IDYA)的"跑赢大市"评级和61.00美元的目标价。该公司的立场是在审查了公司最近关于其药物候选者darolutamide (daro)监管路径的更新后做出的,特别是考虑到积极的二期数据以及FDA对注册试验设计和终点的认可。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
'Harry Potter' star dies
Helene: How to help
Troops to leave some bases
ICE: Convicts roaming free
High-end brothel plea
Pleads not guilty
Killer gets life sentence
Houthis attack US warships
Meta hit with privacy fine
KY sues Express Scripts
Fake Biden robocalls fine
NC dam failure ‘imminent’
Deposition in AI suit
Dow closes at record high
Congestion fee bid denied
Human rabies death in MN
Fed inflation gauge cools
Diocese reaches settlement
Haney sues Garcia
Hezbollah leader killed
Wimbledon expansion OK'd
121st loss of the season
US charges three Iranians
Bill to use birth control
Van Gogh paintings attacked
Congressional Gold Medal
反馈